Perrigo (PRGO) Research & Development (2012 - 2026)
Perrigo's (PRGO) quarterly Research & Development came in at $24.6 million in Q1 2026, down 83.17% year-on-year from $146.2 million in Q1 2025, and up 12.84% on a QoQ basis from $21.8 million in Q4 2025.
Perrigo (PRGO) Research & Development (2012 - 2026) Analysis & Trends
Perrigo (PRGO) has 15 years of Research & Development data on file, last reported at $24.6 million in Q1 2026.
- On a quarterly basis, Research & Development fell 83.17% year-over-year to $24.6 million in Q1 2026; TTM through Mar 2026 was $195.7 million, a 75.05% decrease from a year earlier, with the FY2025 full-year figure at $95.4 million, down 82.55% from the prior year.
- Research & Development for Q1 2026 stood at $24.6 million, up from $21.8 million in the prior quarter.
- Over the last five years, Research & Development for PRGO reached as high as $462.2 million in Q4 2024 and fell as low as -$366.7 million in Q4 2023.
- Historically, Research & Development has averaged $51.5 million across 5 years, with a median of $31.5 million in 2022.
- On a YoY basis, Research & Development climbed as much as 389.62% in 2025 and fell as far as 95.28% in 2025.
- Year by year, Research & Development stood at -$307.9 million in 2022, then decreased by 19.1% to -$366.7 million in 2023, then surged by 226.04% to $462.2 million in 2024, then plunged by 95.28% to $21.8 million in 2025, then advanced by 12.84% to $24.6 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $24.6 million in Q1 2026, $21.8 million in Q4 2025, and $127.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 138.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.04 Bn | 325.50 Mn | 24.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 24.60 Mn |
| Dec 31, 2025 | 21.80 Mn |
| Sep 27, 2025 | 127.30 Mn |
| Jun 28, 2025 | 22.00 Mn |
| Mar 29, 2025 | 146.20 Mn |
| Dec 31, 2024 | 462.20 Mn |
| Sep 28, 2024 | 26.00 Mn |
| Jun 29, 2024 | 150.10 Mn |
| Mar 30, 2024 | 150.30 Mn |
| Dec 31, 2023 | -366.70 Mn |
| Sep 30, 2023 | 150.20 Mn |
| Jul 1, 2023 | 32.20 Mn |
| Apr 1, 2023 | 31.10 Mn |
| Dec 31, 2022 | -307.90 Mn |
| Oct 1, 2022 | 144.50 Mn |
| Jul 2, 2022 | 31.50 Mn |
| Apr 2, 2022 | 29.30 Mn |
| Dec 31, 2021 | -283.00 Mn |
| Oct 2, 2021 | 129.70 Mn |
| Jul 3, 2021 | 139.80 Mn |